Up a level |
2020
Koutzamanidis, Rafaela, Mentzer, Dirk, Knauss, Samuel, Broeckelmann, Paul J., Hassel, Jessica Cecile, Ugurel-Becker, Selma, Pavel, Marianne, Nickel, Florian, Landendinger, Melanie, Fuchs, Florian, Meidenbauer, Norbert, Jefremow, Andre, Manger, Bernhard, Gutzmer, Ralf, Loguai, Carmen, Kaehler, Katharina, Zimmer, Lisa, Berking, Carola, Keller-Stanislawski, Brigitte, Heinzerling, Lucie, Erdrnann, Michael, Kirchberger, Michael C. and Toussaint, Frederic (2020). Serio - Side Effect Registry in Immuno-Oncology. Oncol. Res. Treat., 43. S. 231 - 232. BASEL: KARGER. ISSN 2296-5262
Leiter, Ulrike, Loquai, Carmen, Reinhardt, Lydia, Rafei-Shamsabadi, David, Gutzmer, Ralf, Kaehler, Katharina, Heinzerling, Lucie, Hassel, Jessica C., Glutsch, Valerie, Sirokay, Judith, Schlecht, Nora, Rubben, Albert, Gambichler, Thilo, Schatton, Kerstin, Pfoehler, Claudia, Franklin, Cindy, Terheyden, Patrick, Haferkamp, Sebastian, Mohr, Peter, Bischof, Lena, Livingstone, Elisabeth, Zimmer, Lisa, Weichenthal, Michael, Schadendorf, Dirk, Meiwes, Andreas, Keim, Ulrike, Garbe, Claus, Becker, Jurgen Christian and Ugurel, Selma (2020). Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. J. Immunother. Cancer, 8 (2). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426
2016
Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian ORCID: 0000-0001-8859-4103, Di Giacomo, Anna Maria, Brenner, Nicole, Kaehler, Katharina, Heinzerling, Lucie, Gutzmer, Ralf, Bender, Armin, Gebhardt, Christoffer ORCID: 0000-0001-7090-9584, Romano, Emanuela, Meier, Friedegund, Martus, Peter, Maio, Michele ORCID: 0000-0002-0323-6321, Blank, Christian, Schadendorf, Dirk, Dummer, Reinhard, Ascierto, Paolo A., Hospers, Geke, Garbe, Claus ORCID: 0000-0001-8530-780X and Wolchok, Jedd D. (2016). Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin. Cancer Res., 22 (22). S. 5487 - 5497. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265